Evidence map›Paper›PMID 22156994›Full record

ArticleEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)2012

Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer.

Mark G Alexandrow, Lanxi J Song, Soner Altiok, Jhanelle Gray, Eric B Haura, Nagi B Kumar

Abstract read
In one paragraph

Article in European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 1 synthesis or guideline pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Extracts fromMarine drugs · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. What nature has to offer: Opportunities for immuno-oncology.Journal of food and drug analysis · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Molecular Targets of Natural Compounds with Anti-Cancer Properties.International journal of molecular sciences · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mark G AlexandrowDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612, USA.
Lanxi J Song
Soner Altiok
Jhanelle Gray
Eric B Haura
Nagi B Kumar
Thoracic Surgery Foundation · USUniversity of South Florida · US

Funding

SPORE in Lung CancerP50CA119997 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI GABRILOVICH, DMITRY I · 2008 to 2012
$11.0M
Enhancing neoadjuvant chemotherpay responses with targeted T cellsR01CA140314 · NCI · WAYNE STATE UNIVERSITY · PI BEPLER, GEROLD · 2010 to 2015
$2.5M
Stat3 in EGFR Driven Non-Small Cell Lung CancerR01CA121182 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI HAURA, ERIC B. · 2007 to 2011
$1.6M
Chromatin Remodeling by Cdt1: Role in DNA Replication and TumorigenesisR01CA130865 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2010 to 2014
$1.5M
MCM Helicase as a Novel Target for Pancreatic Cancer TreatmentR21CA155393 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ALEXANDROW, MARK G. · 2011 to 2012
$400k
NCI NIH HHS 1P50-CA119997NCI NIH HHS 1R01 CA121182NCI NIH HHS P50 CA119997NCI NIH HHS R01 CA121182NCI NIH HHS R01 CA130865NCI NIH HHS R01-CA130865NCI NIH HHS R01 CA140314NCI NIH HHS R21 CA155393NCI NIH HHS R21-CA155393
6 · The paper itself

Abstract

Multiple studies from independent groups find evidence for signal transducer and activator of transcription 3 (Stat3) activation in nearly 50% of lung cancers, suggesting a functional role for this target in subsets of lung cancer. On the basis of the existing evidence, we hypothesized that bioavailable curcuminoid complex may modulate lung carcinogenesis, primarily by inhibiting Stat3 activation. With the safety of this being botanically well established, the objective of these studies was to test our hypothesis in vitro and in vivo in an effort to inform the design of a phase II chemoprevention trial in former smokers. We treated non-tumor-derived, normal (but immortalized) human bronchial epithelial cells (AALE) (Lundberg et al., 2002; Pillai et al., 2011) and lung adenocarcinoma-derived cells (H441) with bioactive curcumin C3 complex. Asynchronous cells in each case were treated with curcumin for 24 h, followed by immunoblotting for Stat3 and activated Stat3-P, prior signal of which was used for normalization. We also completed a preclinical trial in which 12 mice were randomly divided into three groups and subjected to 3 days or 9 days of curcumin intraperitoneal injections, followed by analysis of lung tissues for Stat3-P changes and growth suppressive effects of the curcumin. The growth suppressive effects were measured using Cyclin D1 and the replicative helicase subunit, Mcm2, as surrogates for the proliferative capacity of the tissues. In-vitro studies with curcuminoid complex demonstrated that the activity of Stat3 in both normal bronchoepithelial cells and lung cancer-derived cells is sensitive to curcumin exposure. In a dose-dependent manner, curcumin treatment resulted in significant suppression of Stat3 phosphorylation and reduction in the proliferative capacity of both cell types. In the preclinical trial with rodent models, curcumin reduced Stat3-P and the proliferative markers CycD1 and Mcm2 in mice lung tissues in vivo. These culture and preclinical studies indicate that the activity of the Stat3 pathway can be suppressed by curcumin treatment, concomitant with a reduction in cell proliferation, supporting our hypothesis that inhibition of the Stat3 pathway represents at least one important mechanism by which curcumin elicits its effects on the bronchoepithelium. These data provide a rationale for the use of curcumin as a promising chemopreventive agent in high-risk populations such as former smokers.

Indexed as

AnimalsCell LineCurcuminEnzyme InhibitorsFemaleHumansLung NeoplasmsMiceMice, NudeRandom AllocationSTAT3 Transcription FactorCurcuminEnzyme InhibitorsSTAT3 Transcription Factor

Identifiers

PMID22156994
PMCPMC3319490
OpenAlexW2071684105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.